title: Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogs (exenatide) on cognitive function in hepatosteatosis.
abstract: The aims of the study were to evaluate (1) detection of cognitive function changing in rat with hepatosteatosis model and (2) evaluate the effect of GLP-1 analog (exenatide) on cognitive function in hepatosteatosis. In the study group, 30% fructose was given in nutrition water to perform hepatosteatosis for 8 weeks to 18 male rats. Six male rats were chosen as control group and had normal nutrition. Fructose nutrition group were stratified into 3 groups. In first group (n = 6), intracerebroventricular (ICV) infusion of exenatide (n = 6) was given. ICV infusion of NaCl (n = 6) was given to second group. And also, the third group had no treatment. And also, rats were evaluated for passive avoidance learning (PAL) and liver histopathology. Mean levels of latency time were statistically significantly decreased in rats with hepatosteatosis than those of normal rats (P < 0.00001). However, mean level of latency time in rats with hepatosteatosis treated with ICV exenatide was statistically significantly increased than that of rats treated with ICV NaCl (P < 0.001). Memory performance falls off in rats with hepatosteatosis feeding on fructose (decreased latency time). However, GLP-1 ameliorates cognitive functions (increased latency time) in rats with hepatosteatosis and releated metabolic syndrome.
authors.affiliation: Department of Physiology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey.
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbaş
authors.affiliation: Department of Internal Medicine, School of Medicine, Ege University, Izmir, Turkey ; Department of Geriatrics Medicine, Medical Faculty, Ege University, 5th Floor, Bornova, 35100 Izmir, Turkey.
authors.forename: Fulden
authors.initials: F
authors.lastname: Sarac
authors.affiliation: Department of Histology and Embryology, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Aktuğ
authors.affiliation: Department of Physiology, School of Medicine, Ege University, Izmir, Turkey.
authors.forename: Gönül
authors.initials: G
authors.lastname: Peker
mesh_terms: D000818:Animals; D003071:Cognition / Q000187:drug effects*; D004195:Disease Models, Animal; D000077270:Exenatide; D005234:Fatty Liver / Q000188:drug therapy* / Q000503:physiopathology*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D010455:Peptides / Q000627:therapeutic use*; D051381:Rats; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide
references.citation: Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2060-7
references.pmid: 22895667
references.citation: Hypertension. 2005 Oct;46(4):806-11
references.pmid: 16157789
references.citation: J Clin Endocrinol Metab. 1997 Feb;82(2):473-8
references.pmid: 9024239
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1285-90
references.pmid: 19164583
references.citation: Int J Obes (Lond). 2010 Aug;34(8):1341-4
references.pmid: 20351729
references.citation: Atherosclerosis. 2011 Dec;219(2):839-45
references.pmid: 21959256
references.citation: J Am Med Dir Assoc. 2013 Feb;14(2):105-8
references.pmid: 23178166
references.citation: J Nutr Health Aging. 2013;17(6):523-6
references.pmid: 23732548
references.citation: Alcohol Clin Exp Res. 1986;10(6 Suppl):13S-19S
references.pmid: 3544925
references.citation: Neuroreport. 1999 Jun 3;10(8):1643-6
references.pmid: 10501550
references.citation: Neuroscience. 2011 Mar 10;176:396-407
references.pmid: 21129451
references.citation: Age (Dordr). 2012 Oct;34(5):1211-24
references.pmid: 21901364
references.citation: Endocrine. 2009 Apr;35(2):227-32
references.pmid: 19165636
references.citation: Neuroreport. 1999 Sep 29;10(14):2961-4
references.pmid: 10549805
references.citation: Behav Neural Biol. 1987 Jul;48(1):104-27
references.pmid: 3307740
references.citation: Neuropharmacology. 2010 Jun;58(7):1122-9
references.pmid: 20153342
references.citation: Metabolism. 2004 Apr;53(4):454-7
references.pmid: 15045691
references.citation: Diabetes Obes Metab. 2011 Jan;13(1):26-33
references.pmid: 21114600
references.citation: J Mol Neurosci. 2002 Feb-Apr;18(1-2):7-14
references.pmid: 11931352
references.citation: Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6058-63
references.pmid: 20231476
references.citation: Neurobiol Learn Mem. 2009 Oct;92(3):410-6
references.pmid: 19500683
references.citation: Behav Neural Biol. 1994 Mar;61(2):162-9
references.pmid: 8204081
references.citation: Endocrinology. 2010 Sep;151(9):4214-23
references.pmid: 20660072
references.citation: J Nutr. 1993 Jul;123(7):1320-7
references.pmid: 8320569
references.citation: Lancet. 1987 Dec 5;2(8571):1300-4
references.pmid: 2890903
references.citation: Mol Med. 2013 Feb 08;18:1481-90
references.pmid: 23296426
references.citation: J Alzheimers Dis. 2013;35(2):253-65
references.pmid: 23388170
references.citation: Nat Med. 2003 Sep;9(9):1173-9
references.pmid: 12925848
references.citation: Neuroepidemiology. 2010;34(2):83-9
references.pmid: 20016217
references.citation: Neurobiol Aging. 2012 Feb;33(2):265-76
references.pmid: 20359773
references.citation: Pharmacol Biochem Behav. 2011 Sep;99(3):356-64
references.pmid: 21624392
references.citation: Biochem J. 1972 Sep;129(2):439-46
references.pmid: 4643329
references.citation: Exp Neurol. 2007 Feb;203(2):293-301
references.pmid: 17125767
references.citation: Eur J Neurol. 2006 Dec;13(12):1385-8
references.pmid: 17116226
references.citation: Vitam Horm. 2010;84:331-54
references.pmid: 21094907
references.citation: Eur J Nutr. 2011 Oct;50(7):543-51
references.pmid: 21197538
references.citation: Eur J Nutr. 2012 Jun;51(4):445-54
references.pmid: 21800086